Back to Top Skip to main content Skip to sub-navigation

Defending the Homeland: Turning on lifesaving trials at Madigan Army Medical Center

Image of soldier in front of a laptop Janell Cain, a clinical research coordinator at Madigan with the Infectious Disease Clinical Research Program, records the informed consent forms signed by a patient receiving treatment for COVID-19 in the intensive care unit from Madigan’s Virtual Critical Care Center on April 14. Communicating with the patient and nurses via the video equipment, Cain gains the necessary consent to enroll a patient in a study of remdesivir as a COVID-19 treatment without expending personal protective equipment, or exposing anyone to the patient unnecessarily. The IDCRP is a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. (Lt. Col. (Dr.) Christopher Colombo)

Recommended Content:

Coronavirus

MADIGAN ARMY MEDICAL CENTER, Joint Base Lewis-McChord, Wash. – Madigan Army Medical Center, on Joint Base Lewis-McChord, Wash., has been a hotbed for biomedical research for years, highlighted by patented innovations and award winning presentations at national and international scientific meetings.

In response to the COVID-19 global pandemic, Madigan is currently supporting nine research protocols designed to address gaps in knowledge including clinical characteristics of the COVID-19 illness, the impact of nutrition on COVID-19 risk, and the clinical value of convalescent plasma, in which a patient with severe disease is given plasma from someone who has recovered from COVID-19 and therefore has antibodies to it in their blood, to name a few.

Possibly the most notable clinical trial for COVID-19 treatment involves remdesivir, an investigational, broad-spectrum antiviral drug that has shown some promise, in animal trials, in both Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are caused by other coronaviruses.

The trial is sponsored by the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health, and is the first clinical trial in the U.S. to evaluate an experimental treatment for COVID-19.

When the trial began in February, Dr. Anthony Fauci, the director of NIAID and a member of the U.S. Coronavirus Task Force said, “We urgently need a safe and effective treatment for COVID-19. Although remdesivir has been administered to some patients with COVID-19, we do not have solid data to indicate it can improve clinical outcomes. A randomized, placebo-controlled trial is the gold standard for determining if an experimental treatment can benefit patients.”

Madigan is one of 68 international trial sites among 47 in the U.S. and 21 in Europe and Asia. The first enrollee was at the University of Nebraska Medical Center/Nebraska Medicine, in February; he had been on a cruise ship that saw a number of infections.

The initiation of the trial can is described here: https://www.niaid.nih.gov/news-events/nih-clinical-trial-remdesivir-treat-covid-19-begins.

Within two months of initiation, the clinical trial of remdesivir has produced encouraging results.

In a statement issued on April 29, the NIAID reported, “Preliminary results indicate that patients who received remdesivir had a 31 percent faster time to recovery than those who received placebo (p<0.001). Specifically, the median time to recovery was 11 days for patients treated with remdesivir compared with 15 days for those who received placebo. Results also suggested a survival benefit, with a mortality rate of 8.0 percent for the group receiving remdesivir versus 11.6 percent for the placebo group (p=0.059).”

This trial is managed at Madigan by the Infectious Disease Clinical Research Program, a Department of Defense-wide research consortium headquartered at the Uniformed Services University for the Health Sciences in Bethesda, Md. The IDCRP conducts clinical research that focuses on reducing the impact of infectious diseases relevant to the DoD.

For more information about the IDCRP, visit: https://www.idcrp.org/about-us.

The IDCRP has a broad research portfolio, including an ongoing study looking at the efficacy of different formulations of the flu vaccine. When COVID-19 emerged, the IDCRP pivoted to get this research up and running in a very short period of time. As an established IDCRP site, Madigan was identified as one of the military treatment facilities eligible for participation in the NIAID trial.

“Because they are so active and such a squared-away group, they were able to help get this trial off the ground,” said Lt. Col. (Dr.) Christopher Colombo, principal investigator for the COVID-19 trial and the director of Virtual Health and Telecritical Care at Madigan.

Madigan has strong and adaptive biomedical research capabilities that are facilitated by its Department of Clinical Investigation.

“The Department of Clinical Investigation, Dr. Rick Burney (DCI’s chief) and Dr. (Silvija) Salai (the human subject protection administrator), have been fantastic in supporting and expediting this and balancing making sure that everything is still done dress-right-dress according to regulatory, safety and scientific integrity filings, but it is going quite a bit faster than usual, because of the situation that we're in,” noted Lt. Col. Colombo.

Madigan is one of five DoD sites that has enrolled patients in the study so far and is already ramping up for its next phase. Investigators stress that these are early days of evaluation for this trial. Given the high transmissibility and global spread of this virus, research has moved quickly.

“It's a placebo controlled trial, so the patients are randomized. We don't know who's getting what. They either get placebo or remdesivir,” Lt. Col. Colombo said.

NIH requirements for inclusion in the trial comprise the need for hospitalization for documented COVID-19 infection and either an abnormal chest x-ray or the requirement for supplemental oxygen or mechanical ventilation. Trial participation is limited to adults.

Participants in the treatment group get 200 milligrams (mg) of remdesivir injected on the first day they are in the study and 100 mg each day of their hospitalization, up to 10 days total. Those in the placebo group receive the same amount of what looks like remdesivir but contains only inactive ingredients.

This means the trial is administered to patients currently being treated in the hospital, though some have since improved and gone home. They return to the hospital periodically for monitoring.

Dr. Rhonda Colombo, an infectious diseases physician who works in support of the IDCRP at Madigan, praised the contributions of patients who volunteered to participate in this and other ongoing clinical research trials.

“Without willing and engaged study participants, clinical research is not possible. At Madigan, we are incredibly fortunate to be part of a community that values clinical research. Our research team is humbled by the generosity and commitment of the people who volunteer to participate in our studies,” said Dr. Colombo.

With drug safety and long-term effects always in mind, the team is not yet ready to draw conclusions, but is optimistic about the data so far.

Susan Chambers, the clinical operations manager for the IDCRP at Madigan echoed that appreciation for the high value that Madigan, and the JBLM community place on research, noting that it is the providers and nurses on the inpatient units who directly support research within their care of patients.

“We are incredibly proud to have the opportunity to offer access to cutting-edge research for our Active Duty personnel and DoD beneficiaries. Our success would not be possible without the support of Madigan Commander Col. Thomas Bundt and the committed inpatient clinical care teams at Madigan,” said Chambers.

On Friday, May 1, the U.S. Food and Drug Administration gave remdesivir emergency use authorization to treat COVID-19.

The NIAID expects to share additional data soon, as well as next steps.

“We managed to get meaningful research turned on, very quickly. Other sites in the Department of Defense, are kind of looking at Madigan like you guys are knocking it out of the park, keep going,” said Lt. Col. Colombo. “I think it's something that's cool in terms of how we're responding to COVID in a positive way and making some good come of this.”

Disclaimer: Re-published content may be edited for length and clarity.  Read original post.

You also may be interested in...

MHS Minute: A Call to Action for Convalescent Plasma Donation

Video
8/24/2020
Image of MHS Minute Carousel

Have you recovered from COVID-19, or tested positive for antibodies? Consider donating convalescent plasma. For eligibility requirements, and to find a donor center near you, go to https://www.militaryblood.dod.mil/Donors/COVID-19andBloodDonation.aspx

Recommended Content:

Coronavirus | Convalescent Plasma Collection Program | COVID-19 Vaccine Toolkit | Armed Services Blood Program

Convalescent Plasma Donation PSA featuring Lt. General Place

Video
7/10/2020
Image of Lt. Gen Place

Lt. Gen Place asks servicemembers DoD-wide to consider dontating plasma in the fight against COVID-19.

Recommended Content:

Coronavirus | Convalescent Plasma Collection Program | COVID-19 Vaccine Toolkit | Armed Services Blood Program

MHS Minute: DoD Focused on COVID-19 Testing and Treatment

Video
6/25/2020
Image of MHS Minute Carousel

Have you recovered from COVID-19, or tested positive for antibodies? Consider donating convalescent plasma. To learn how, go to https://www.militaryblood.dod.mil/

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit

MHS Minute: Military Leading the Charge on COVID-19 Research

Video
5/28/2020
Image of MHS Minute Carousel

The military continues to serve on the front lines of research and treatment in response to the COVID-19 pandemic. Tune in to the MHS Minute to learn more.

Recommended Content:

Coronavirus

Transport Vent Tutorial (ParaPAC) (March 25, 2020)

Video
5/11/2020
DHA Seal

Transport Vent Tutorial - ParaPAC

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit

Multi-Dimensional Approach To Intubation In The Setting Of COVID-19 (April 1, 2020)

Video
5/11/2020
DHA Seal

In this video, a doctor and nurse will talk you through preparing to intubate a patient. At the end of the video we highlight some special considerations for intubation in the context of COVID.

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit

Shock Basics for the Non-Intensivist (March 19, 2020)

Video
5/11/2020
DHA Seal

Shock Basics for the Non-Intensivist...in the age of COVID-19.

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit

Airway Pressure Release Ventilation (APRV) (April 17, 2020)

Video
5/11/2020
DHA Seal

This video will explain the basics of Airway Pressure Release Ventilation, an option for mechanical ventilation, that is helpful as an oxygen salvage therapy for patients with Acute Respiratory Distress Syndrome (ARDS).

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit

Sedation and Analgesia in the ICU during COVID-19 (March 31, 2020)

Video
5/11/2020
DHA Seal

This video is intended to assist healthcare providers with the care of critically ill patients only. It is to be used as a guide ONLY for patients who have breathing tubes and are mechanically ventilated (on breathing machines). It will introduce you to sedative and analgesic medications that are used in the intensive care unit setting only. It will provide recommendations for use of sedation and analgesia in standard settings, but it will also provide recommendations for use in resource limited

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit

Ventilator Basics - Part 2 (ACPC and PS) (March 25, 2020)

Video
5/11/2020
DHA Seal

This video is an introduction to pressure control and pressure support ventilator settings. If you have not yet viewed 'Vent Basics for Non-Intensivists (ACVC/VAC)", please watch that video first. This video is not intended to be all encompassing. It is intended to educate non-intensivists on basic vent settings and vent mechanics.

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit

Acute Respiratory Distress Syndrome Lecture (April 10, 2020)

Video
5/11/2020
DHA Seal

In this lecture, the topic or Acute Respiratory Distress Syndrome is reviewed. Specific discussion on diagnosis and treatment including lung protective strategies are discussed.

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit

IV Vasoactive Medication Basics for the Non Intensivist (March 19, 2020)

Video
5/11/2020
DHA Seal

This video provides a refresher/introduction to the basics of inotropes and vasopressors that may be helpful in the context of treating COVID-19 patients. It is not intended to be all-encompassing.

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit

Ventilator Basics (ACVC) (March 19, 2020)

Video
5/11/2020
DHA Seal

Ventilator basics (one mode) for non-intensivists

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit

Ventilator Tutorial V500/PB840 Drager (April 10, 2020)

Video
5/11/2020
DHA Seal

Ventilator assembly and input of settings for two common ICU ventilators.

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit

Acid Base for the Non-intensivist (March 21, 2020)

Video
5/11/2020
DHA Seal

This video will teach you the etiologies for the various acid-base disorders as well as teach you how to interpret an ABG with a focus on metabolic acidosis and mixed disorders. This will teach you little to nothing about buffering, organic chemistry, biochemistry, etc. This is for practical application at the bedside.

Recommended Content:

Coronavirus | COVID-19 Vaccine Toolkit
<< < 1 2 3 4 > >> 
Showing results 31 - 45 Page 3 of 4

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.